Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera

British Journal of Haematology

Volumn 175, Issue 3, 2016, Pages 419-426

  Delic, Sabit ^a   Rose, Dominic ^a   Kern, Wolfgang ^a   Nadarajah, Niroshan ^a   Haferlach, Claudia ^a   Haferlach, Torsten ^a   Meggendorfer, Manja ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

epigenetic; essential thrombocythaemia; polycythaemia vera; primary myelofibrosis; splicing

Indexed keywords

DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; TRANSCRIPTION FACTOR EZH2; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; ASXL1 GENE; CHROMATIN; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA METHYLATION; DNA MODIFICATION; DNMT3A GENE; EZH2 GENE; FEASIBILITY STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; IDH1 GENE; IDH2 GENE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NEXT GENERATION SEQUENCING; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; RNA SPLICING; SF3B1 GENE; SRSF2 GENE; TET2 GENE; THROMBOCYTHEMIA; U2AF1 GENE; VALIDATION STUDY; DIFFERENTIAL DIAGNOSIS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC EPIGENESIS; GENETIC SCREENING; GENETICS; HIGH THROUGHPUT SEQUENCING; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; MYELOPROLIFERATIVE DISORDERS; PRIMARY MYELOFIBROSIS; THROMBOCYTHEMIA, ESSENTIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; EPIGENESIS, GENETIC; FEMALE; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; MUTATION RATE; MYELOPROLIFERATIVE DISORDERS; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; RNA SPLICING; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84992448488     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14269     Document Type: Article

References (22)

1. Abdel-Wahab, O., Manshouri, T., Patel, J., Harris, K., Yao, J., Hedvat, C., Heguy, A., Bueso-Ramos, C., Kantarjian, H., Levine, R.L. & Verstovsek, S. (2010) Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Research, 70, 447–452.
2. Brecqueville, M., Rey, J., Bertucci, F., Coppin, E., Finetti, P., Carbuccia, N., Cervera, N., Gelsi-Boyer, V., Arnoulet, C., Gisserot, O., Verrot, D., Slama, B., Vey, N., Mozziconacci, M.J., Birnbaum, D. & Murati, A. (2012) Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms. Genes Chromosomes. Cancer, 51, 743–755.
3. Geyer, H.L. & Mesa, R.A. (2014) Therapy for myeloproliferative neoplasms: when, which agent, and how? Blood, 124, 3529–3537.
4. Grossmann, V., Roller, A., Klein, H.U., Weissmann, S., Kern, W., Haferlach, C., Dugas, M., Haferlach, T., Schnittger, S. & Kohlmann, A. (2013) Robustness of amplicon deep sequencing underlines its utility in clinical applications. The Journal of Molecular Diagnostics, 15, 473–484.
5. Guglielmelli, P., Lasho, T.L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., Biamonte, F., Pardanani, A., Zoi, K., Reiter, A., Duncombe, A., Fanelli, T., Pietra, D., Rumi, E., Finke, C., Gangat, N., Ketterling, R.P., Knudson, R.A., Hanson, C.A., Bosi, A., Pereira, A., Manfredini, R., Cervantes, F., Barosi, G., Cazzola, M., Cross, N.C., Vannucchi, A.M. & Tefferi, A. (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 28, 1804–1810.
6. Klampfl, T., Gisslinger, H., Harutyunyan, A.S., Nivarthi, H., Rumi, E., Milosevic, J.D., Them, N.C., Berg, T., Gisslinger, B., Pietra, D., Chen, D., Vladimer, G.I., Bagienski, K., Milanesi, C., Casetti, I.C., Sant'Antonio, E., Ferretti, V., Elena, C., Schischlik, F., Cleary, C., Six, M., Schalling, M., Schonegger, A., Bock, C., Malcovati, L., Pascutto, C., Superti-Furga, G., Cazzola, M. & Kralovics, R. (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. New England Journal of Medicine, 369, 2379–2390.
7. Kralovics, R., Passamonti, F., Buser, A.S., Teo, S.S., Tiedt, R., Passweg, J.R., Tichelli, A., Cazzola, M. & Skoda, R.C. (2005) A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders. New England Journal of Medicine, 352, 1779–1790.
8. Lasho, T.L., Finke, C.M., Hanson, C.A., Jimma, T., Knudson, R.A., Ketterling, R.P., Pardanani, A. & Tefferi, A. (2012) SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients. Leukemia, 26, 1135–1137.
9. Lundberg, P., Karow, A., Nienhold, R., Looser, R., Hao-Shen, H., Nissen, I., Girsberger, S., Lehmann, T., Passweg, J., Stern, M., Beisel, C., Kralovics, R. & Skoda, R.C. (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood, 123, 2220–2228.
10. Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C., Avezov, E., Li, J., Kollmann, K., Kent, D.G., Aziz, A., Godfrey, A.L., Hinton, J., Martincorena, I., Van, L.P., Jones, A.V., Guglielmelli, P., Tarpey, P., Harding, H.P., Fitzpatrick, J.D., Goudie, C.T., Ortmann, C.A., Loughran, S.J., Raine, K., Jones, D.R., Butler, A.P., Teague, J.W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.Q., Greaves, M., Bowen, D., Huntly, B.J., Harrison, C.N., Cross, N.C., Ron, D., Vannucchi, A.M., Papaemmanuil, E., Campbell, P.J. & Green, A.R. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369, 2391–2405.
11. Ortmann, C.A., Kent, D.G., Nangalia, J., Silber, Y., Wedge, D.C., Grinfeld, J., Baxter, E.J., Massie, C.E., Papaemmanuil, E., Menon, S., Godfrey, A.L., Dimitropoulou, D., Guglielmelli, P., Bellosillo, B., Besses, C., Dohner, K., Harrison, C.N., Vassiliou, G.S., Vannucchi, A., Campbell, P.J. & Green, A.R. (2015) Effect of mutation order on myeloproliferative neoplasms. New England Journal of Medicine, 372, 601–612.
12. Pardanani, A.D., Levine, R.L., Lasho, T., Pikman, Y., Mesa, R.A., Wadleigh, M., Steensma, D.P., Elliott, M.A., Wolanskyj, A.P., Hogan, W.J., McClure, R.F., Litzow, M.R., Gilliland, D.G. & Tefferi, A. (2006) MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood, 108, 3472–3476.
13. Rohrbacher, M., Berger, U., Hochhaus, A., Metzgeroth, G., Adam, K., Lahaye, T., Saussele, S., Muller, M.C., Hasford, J., Heimpel, H. & Hehlmann, R. (2009) Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in Germany. Leukemia, 23, 602–604.
14. Scott, L.M., Tong, W., Levine, R.L., Scott, M.A., Beer, P.A., Stratton, M.R., Futreal, P.A., Erber, W.N., McMullin, M.F., Harrison, C.N., Warren, A.J., Gilliland, D.G., Lodish, H.F. & Green, A.R. (2007) JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis. New England Journal of Medicine, 356, 459–468.
15. Shih, A.H., bdel-Wahab, O., Patel, J.P. & Levine, R.L. (2012) The role of mutations in epigenetic regulators in myeloid malignancies. Nature Reviews. Cancer, 12, 599–612.
16. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Thiele, J. & Vardiman, J.W. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer Press, Lyon, France.
17. Tefferi, A., Pardanani, A., Lim, K.H., bdel-Wahab, O., Lasho, T.L., Patel, J., Gangat, N., Finke, C.M., Schwager, S., Mullally, A., Li, C.Y., Hanson, C.A., Mesa, R., Bernard, O., Delhommeau, F., Vainchenker, W., Gilliland, D.G. & Levine, R.L. (2009) TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia, 23, 905–911.
18. Tefferi, A., Lasho, T.L., Finke, C.M., Knudson, R.A., Ketterling, R., Hanson, C.H., Maffioli, M., Caramazza, D., Passamonti, F. & Pardanani, A. (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia, 28, 1472–1477.
19. Tenedini, E., Bernardis, I., Artusi, V., Artuso, L., Roncaglia, E., Guglielmelli, P., Pieri, L., Bogani, C., Biamonte, F., Rotunno, G., Mannarelli, C., Bianchi, E., Pancrazzi, A., Fanelli, T., Malagoli Tagliazucchi, G., Ferrari, S., Manfredini, R., Vannucchi, A.M. & Tagliafico, E. (2014) Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia, 28, 1052–1059.
20. Vannucchi, A.M., Lasho, T.L., Guglielmelli, P., Biamonte, F., Pardanani, A., Pereira, A., Finke, C., Score, J., Gangat, N., Mannarelli, C., Ketterling, R.P., Rotunno, G., Knudson, R.A., Susini, M.C., Laborde, R.R., Spolverini, A., Pancrazzi, A., Pieri, L., Manfredini, R., Tagliafico, E., Zini, R., Jones, A., Zoi, K., Reiter, A., Duncombe, A., Pietra, D., Rumi, E., Cervantes, F., Barosi, G., Cazzola, M., Cross, N.C. & Tefferi, A. (2013) Mutations and prognosis in primary myelofibrosis. Leukemia, 27, 1861–1869.
21. Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., Chalkidis, G., Suzuki, Y., Shiosaka, M., Kawahata, R., Yamaguchi, T., Otsu, M., Obara, N., Sakata-Yanagimoto, M., Ishiyama, K., Mori, H., Nolte, F., Hofmann, W.K., Miyawaki, S., Sugano, S., Haferlach, C., Koeffler, H.P., Shih, L.Y., Haferlach, T., Chiba, S., Nakauchi, H., Miyano, S. & Ogawa, S. (2011) Frequent pathway mutations of splicing machinery in myelodysplasia. Nature, 478, 64–69.
22. Zhang, S.J., Rampal, R., Manshouri, T., Patel, J., Mensah, N., Kayserian, A., Hricik, T., Heguy, A., Hedvat, C., Gonen, M., Kantarjian, H., Levine, R.L., bdel-Wahab, O. & Verstovsek, S. (2012) Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood, 119, 4480–4485.